Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai-Reference-Cited by-同舟云学术

Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai

Published:2013-07-28 Issue:9 Volume:139 Page:1579-1589
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Cai Xun,Cao Weiguo,Ding Honghua,Liu Tianshu,Zhou Xinli,Wang Mei,Zhong Ming,Zhao Ziyi,Xu Qing,Wang Liwei

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/article/10.1007/s00432-013-1480-7/fulltext.html

Reference32 articles.

1. Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F, Barrett JH et al (2008) Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol 26(16):2690–2698

2. Canal P, Gay C, Dezeuze A, Douillard JY, Bugat R, Brunet R, Adenis A, Herait P, Lokiec F, Mathieu-Boue A (1996) Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 14(10):2688–2695

3. Chang DZ, Kumar V, Ma Y, Li K, Kopetz S (2009) Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy. J Hematol Oncol 2:18

4. Charasson V, Bellott R, Meynard D, Longy M, Gorry P, Robert J (2004) Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38. Clin Pharmacol Ther 76(6):528–535

5. Côté JF, Kirzin S, Kramar A, Mosnier JF, Diebold MD, Soubeyran I, Thirouard AS, Selves J, Laurent-Puig P, Ychou M (2007) UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 13(11):3269–3275

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Simultaneous determination of 11 oral targeted antineoplastic drugs and 2 active metabolites by LC-MS/MS in human plasma and its application to therapeutic drug monitoring in cancer patients;Journal of Chromatography B;2024-04

2. UGT1A1 genotype‐guided irinotecan dosing during neoadjuvant chemoradiotherapy for locally advanced rectal cancer: A prospective analysis of SN‐38 concentration;International Journal of Cancer;2023-12-29

3. Genotyping of UGT1A1*80 as an Alternative to UGT1A1*28 Genotyping in Spain;Pharmaceutics;2022-09-29

4. TaqMan real time PCR for the Detection of the Gilbert’s Syndrome Markers UGT1A1*28; UGT1A1*36 and UGT1A1*37;Molecular Biology Reports;2021-06-04

5. Cost–effectiveness analysis of UGT1A1*6/*28 genotyping for preventing FOLFIRI-induced severe neutropenia in Chinese colorectal cancer patients;Pharmacogenomics;2019-03